Budget vs premium
Gala vs Embody: Which Costs Less Over 12 Months? (2026)
Gala or Embody? Side-by-side 2026 pricing, medication and service comparison, extended to six and twelve-month totals.
Published · Pricing as published in our provider dataset, synced · Editorial scores 7.7 and 7.6 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
The choice between Gala and Embody usually comes down to one difference that neither homepage puts in its headline.
The gap is 3.6x: $69/mo at Embody, $249/mo at Gala. Neither number is unusual for the market, but paying the higher one only makes sense if you can name what it adds.
The comparison below starts from published pricing, converts it into annual cost, and then asks what the more expensive side is delivering for the difference. Anything a provider declines to disclose is marked undisclosed rather than filled in.
The short answer
- Lowest 12-month cost
- Embody — $828 against $2,148 at Gala, on each provider's own best published pricing.
- Most support for the money
- Gala — Provider check-ins and dose monitoring included.
- Tirzepatide access
- Embody — Tirzepatide at $119/mo; the other side publishes semaglutide only.
- Easiest to pay for
- Gala — Neither publishes financing; both expect the full amount monthly.
Side-by-side comparison
The rows below are the ones that differ enough between these two to be worth your attention.
| Gala | Embody | |
|---|---|---|
| Advertised price | From $249/mo, as low as $179/mo on longer plans | Semaglutide $69/mo (was $299), tirzepatide $119/mo |
| Rate after promotions | $249/mo | $69/mo |
| Pricing structure | Cheaper per month the longer you commit | Published rate per medication |
| Medication | Compounded semaglutide and compounded tirzepatide | Compounded semaglutide and compounded tirzepatide |
| Payment options | Card only, no financing published | Card only, no financing published |
| Membership fee | None | None |
| How fast you start | Fully online, no in-office visits | Licensed provider review handled entirely online |
| State coverage | Not published | Not published |
| Patient reviews | 2,870 | 11,250 |
| eRxDoctor score | 7.7/10 | 7.6/10 |
Cost over a full course of treatment
Comparing entry prices across these two would be actively misleading, because they escalate differently. Here is what each one costs across a realistic course of treatment, on published pricing.
| Gala | Embody | |
|---|---|---|
| First month | $249 | $69 |
| Months 2 onward | $249/mo | $69/mo |
| 6-month total | $1,494 | $414 |
| 12-month total | $2,988 | $828 |
| Best published plan | longer-term plan at $179/mo — $2,148/yr | No multi-month discount published |
The twelve-month spread is $1,320. That is the number to hold Gala against: it has to justify roughly $110 extra every month.
Is Gala worth the premium?
Before treating the cheaper option as the obvious one, it is worth naming what the more expensive one includes — at Gala that is provider check-ins and dose monitoring included, plus home delivery.
Embody counters with the lowest published semaglutide price on this list, with no lock-in, and the thing it asks you to accept in return: a limited-time rate with few of the extras that higher-priced platforms bundle.
Price gaps in this market rarely reflect a different molecule; they reflect a different amount of human contact. Decide how much of that you actually intend to use before paying for it.
Gala in detail
Gala positions itself on a direct-pay model with dose monitoring included rather than sold as an add-on. Gala GLP-1 is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide with provider check-ins and home delivery.
Practically: fully online, no in-office visits, home delivery, and a pricing model that is cheaper per month the longer you commit.
Ongoing care is provider check-ins and dose monitoring included, and the medication list runs to compounded semaglutide and compounded tirzepatide.
Gala pros
- Direct-pay model, no insurance or prior authorizations needed
- Provider check-ins and dose monitoring included
- Fully online, no in-office visits required
Gala cons
- Lower long-term pricing requires a multi-month commitment
- Higher entry price than several compounded competitors
The reservation worth holding, particularly next to Embody: the entry price sits above most compounded competitors unless you commit to a longer term.
Embody: what you are buying
Semaglutide $69/mo (was $299), Tirzepatide $119/mo Against Gala, that puts it in the position of the cheaper option.
From signup to first shipment: licensed provider review handled entirely online, then free shipping, 1-2 day delivery after approval. Billing follows a published rate per medication structure.
Support: 24/7 support for dosing and side-effect questions. The medications on offer are compounded semaglutide and compounded tirzepatide.
Embody pros
- Compounded tirzepatide available at $119/month
- Lowest entry price on this list at $69/month for compounded semaglutide
- No long-term commitment; cancel without penalty
- Free shipping with fast 1–2 day delivery after approval
Embody cons
- Compounded medication only, no branded Ozempic, Wegovy, or Zepbound
- Fewer premium features (no integrated coaching or advanced monitoring) than higher-priced platforms
- Final pricing may vary based on dose and clinician recommendation
Read next to Gala, the weak point: a limited-time rate with few of the extras that higher-priced platforms bundle.
Who each program is actually built for
Choose Gala if:
- you want to start on their timeline: fully online, no in-office visits
- the level of clinical contact suits you: provider check-ins and dose monitoring included
- you would get real value from a direct-pay model with dose monitoring included rather than sold as an add-on
- you are willing to commit for a term in exchange for a lower effective rate (longer-term plan at $179/mo)
Choose Embody if:
- the monthly rate is the constraint — $69/mo against $249/mo
- you want tirzepatide available without changing provider later
- the twelve-month total is what you are optimizing ($828 against $2,988)
- you would get real value from the lowest published semaglutide price on this list, with no lock-in
Honest trade-offs
On price. $69/mo against $249/mo. Gala is asking you to pay for a direct-pay model with dose monitoring included rather than sold as an add-on; decide whether that is a line item you will use.
On commitment. Gala rewards a longer commitment (longer-term plan at $179/mo), which lowers the effective rate but ties up money before you know how you respond to the medication. Neither publishes financing options, so plan for the full amount each month.
On clinical contact. Provider check-ins and dose monitoring included at Gala; 24/7 support for dosing and side-effect questions at Embody. Neither is a substitute for in-person care if you have complicating conditions, and both bill you directly rather than your insurer.
On medication. Gala covers compounded semaglutide and compounded tirzepatide; Embody covers compounded semaglutide and compounded tirzepatide. Only Embody publishes a tirzepatide route, which matters if semaglutide underdelivers.
What the trials and the FDA say
It is worth separating the program from the pharmacology. What follows is true of the medication regardless of which of these two writes the prescription.
The FDA publishes an ongoing record of semaglutide products marketed for diabetes and weight loss, and which of them it has actually approved, per FDA.
Dosing errors are the failure mode the FDA has flagged most often with unapproved GLP-1 products, particularly where a patient draws the dose themselves, per FDA.
Neither platform's marketing changes any of that. It is the same evidence base whichever one takes your card.
Gala vs Embody: common questions
Which is cheaper to start, Gala or Embody?
Embody, at $69 against $249. Note that the cheapest first month and the cheapest year are often different providers here — check the 12-month row of the cost table before deciding on the entry price.
How fast can I start with Gala compared with Embody?
Gala advertises fully online, no in-office visits, with home delivery. Embody advertises licensed provider review handled entirely online, with free shipping, 1-2 day delivery after approval. Both are subject to clinician review and to whether your state and health history clear, so treat the advertised timeline as a best case rather than a commitment.
What happens if I stop taking the medication?
Neither Gala nor Embody penalizes you for stopping, but the medication does. The published follow-up data on withdrawal shows substantial regain, which is why the twelve-month totals above matter more than either provider's introductory offer.
Are Gala and Embody legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Gala operates on cheaper per month the longer you commit with pricing published upfront, Embody on published rate per medication, published upfront. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
Can I switch from Gala to Embody later?
Yes. Neither program locks you in clinically, and both operate month to month unless you have bought a multi-month plan. Practically, switching means a fresh intake, a fresh clinician review and possibly a gap in supply, so time it against your current shipment rather than your renewal date, and check the refund terms on any prepaid plan first.
Is Gala or Embody better for a first GLP-1 prescription?
If this is your first GLP-1, the question is who answers when nausea arrives on day nine. Gala publishes provider check-ins and dose monitoring included, which is the more useful thing to buy at the start.
Do Gala and Embody prescribe the same medication?
Both dispense compounded GLP-1 preparations. Gala lists compounded semaglutide and compounded tirzepatide and Embody lists compounded semaglutide and compounded tirzepatide, so the molecules overlap even where the formulary does not match exactly.
The verdict
Embody is the cheaper year by $1,320, and for a straightforward course of treatment that settles it.
The case for Gala is a direct-pay model with dose monitoring included rather than sold as an add-on. That is worth $110 a month to some patients and nothing at all to others — be honest about which you are.
Neither choice is irreversible. Start with the program whose weaknesses you can tolerate, and reassess at month three when you know how you respond to the medication.
Keep comparing
- Gala vs Elevate HealthBudget vs premium
- Gala vs TMatesLarge platform vs smaller platform
- Embody vs Elevate HealthBudget vs premium
- Embody vs TMatesBudget vs premium
- LIV Body vs MaximusBudget vs premium
- Mochi Health vs TMatesBudget vs premium
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Gala or Embody, and does not sell treatment. Read our ranking methodology.